New approaches for managing antiphospholipid syndrome

Nature Clinical Practice Rheumatology

Volumn 5, Issue 3, 2009, Pages 160-170

  Erkan, Doruk ^a   Lockshin, Michael D ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; FONDAPARINUX; HEPARIN; HIRULOG; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PLACEBO; RITUXIMAB; ROSUVASTATIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; B CELL LYMPHOMA; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOMODULATION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; NONHUMAN; PLASMAPHERESIS; PREGNANCY COMPLICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; THROMBOSIS;

EID: 62849100961     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum1017     Document Type: Review

References (81)

1. Miyakis S et al. (2006) International consensus statement on an update of the preliminary classification criteria for antiphospholipid syndrome. J Thromb Haemost 4: 295-306
2. Erkan D and Lockshin MD (2004) What is antiphospholipid syndrome? Curr Rheumatol Rep 6: 451-457
3. Lim W et al. (2006) Management of antiphospholipid antibody syndrome: A systematic review. JAMA 295: 1050-1057
4. Ruiz-Irastorza G et al. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57: 1487-1495
5. Erkan D et al. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56: 2382-2391
6. Erkan D et al. (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41: 924-929
7. Goldstein LB et al. (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Circulation 113: E873-923
8. Khamashta MA et al. (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993-997
9. Levine SR et al. (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291: 576-584
10. Fonseca AG and D'Cruz DP (2008) Controversies in the management of the antiphospholipid syndrome: Can we ever stop warfarin? J Autoimmune Dis 5: 6
11. Schulman S et al. (1998) Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with various thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 104: 332-338
12. Crowther MA et al. (2003) Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with tihe antiphospholipid antibody syndrome. N Engl J Med 349: 1133-1138
13. Finazzi G. et al. (2005) A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3: 848-853
14. Kasthuri RS and Roubey RAS (2007) Warfarin and the antiphospholipid syndrome. Does one size fit all? Arthritis Rheum 57: 1346-1347
15. Kaul M et al. (2005) Warfarin alternatives for secondary thrombosis prophylaxis in antiphospholipid syndrome. Arthritis Rheum 52: S595 (abstract)
16. Dentali F et al. (2005) Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 3:2121-2123
17. Weitz, JI et al. (2004) Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004: 424-438
18. Girardi G et al. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10: 1222-1226
19. Weitz JI et al. (2008) New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl 6): S234-S256
20. Vora SK et al. (2006) Catastrophic antiphospholipid syndrome. J Intensive Care Med 21: 144-159
21. Franklin RD and Kutteh WH (2003) Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 101: 455-462
22. Scheinman RI et al. (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283-286
23. 2-glycoprotein 1 antibodies. Thromb Heemost 88: 851-857
24. Raschi E et al. (2003) Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 101: 3495-3500
25. Nimmerjahn F and Ravetch JV (2007) The anti-inflammatory activity of IgG: The intravenous IgG paradox. J Exp Med 204: 11-15
26. Pierangeli SS et al. (2001) Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced-thrombogenic phenotype. Arthritis Rheum 44: 876-883
27. Uthman I et al. (2005) The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 33: 11-17
28. Bayraktar UD et al. (2007) The clinical spectrum of catastrophic anti phospholipid syndrome in the absence and presence of lupus. J Rheumatol 34: 346
29. Erkan D (2006) Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6: 98-103
30. Erkan D et al. (2003) Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 62: 530-533
31. Empson M et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD002859. doi:10.1002/ 14651858.CD002859.pub2
32. Rai R et al. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314: 253-257
33. Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174: 1584-1589
34. Erkan D et al. (2008) Management of the controversial aspects of the antiphospholipid syndrome pregnancies: A guide for clinicians and researchers. Rheumatology (Oxford) 47 (Suppl 3): Iii23-iii27
35. Branch DW et al. (2001) Obstetric uses of intravenous immunoglobulin: Successes, failures, and promises. J Allergy Clin Immunol 108 (Suppl 4): 133-138
36. Pieraingeli SS et al. (2007) New targeted therapies for treatment of thrombosis in antiphospholipid syndrome. Empert Rev Mol Med 9: 1-15
37. Jancinova V et al. (1994) On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb Res 74: 495-504
38. Lombard-Platlet S et al. (1993) Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of enclogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T cell. Immunology 80: 566-573
39. Goldman FD et al. (2000) Hydroxychloroquine inhibits calcium signals in T cells: A new meuhanism to explain its immunomodulatory properties. Blood 95: 3460-3466
40. Pierangeli SS et al. (2004) Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: A pathway to targeted therapies. Thromb Res 114: 467-476
41. Rand JH et al. (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112: 1687-1695
42. Johnson R and Chamley J (1979) Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 144: 174-177
43. Wallace DJ (1987) Does hydroxychloroquine protect against clot formation in systemic lupus erythematosus? Arthritis Rheum 30: 1435-1436
44. Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5 (Suppl 1 S16-S22
45. Kaiser R et al. (2008) Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort. Ann Rheum Dis [doi:10.1136/ard.2008.093013]
46. Ruiz-Irastorza G et al. (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15: 577-583
47. Ho KT et al. (2005) Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 44: 1303-1307
48. McCarty GA and Cason TE (2004) Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: Improvement in antibody titer and symptoma management. 7th International Congress on SLE and related conditions abstract book M17A [abstract]
49. Erkan D et al. (2005) Real world experience with antiphospholipid antibodies (aPL). How stable and significant are aPL? Ann Rheum Dis 64: 1321-1325
50. Ferrara DE et al. (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48: 3272-3279
51. Meroni P et al. (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44: 2870-2878
52. Ferrara DE et al. (2004) Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2: 1558-1563
53. Martinez et al. (2007) Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model [abstract]. Clin Exp Rheumatol 25: 18-19
54. Cuadrado MJ et al. (2007) Changes operated in protein pattern of monocytes from patients with antiphospholipid syndrome treated with statins [abstract]. Arthritis Rheum 56 (suppl): 782-783
55. Kumar et al. (2008) Effects of fluvastatin on prothrombotic/ proinflammatory markers in patients with antiphospholipid syndrome [abstract]. Arthritis Rheum 58 (suppl): 172
56. Ridker PM et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207
57. Molina A (2008) A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59: 237-250
58. Erre GL et al. (2008) Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: A case report and a review of literature. Lupus 17: 50-55
59. Tenedious F et al. (2005) Rituximab in the primary antiphospholipid antibody syndrome [abstract]. Arthritis Rheum 52: 4078
60. Youinou P and Reneaudineau Y (2004) The antiphospholipid syndrome as a model for B-cell-induced autoimmune diseases. Thromb Res 114 363-369
61. Kahn P et al. (2008) Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 58: 2824-2834
62. A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS). [http://clinicaltrials.gov/ct2/show/NCT00537290?term= NCT00537290&rank=1] (accessed 14 January 2009)
63. Salmon JE et al. (2007) The antiphospholipid syndrome as a disorder initiated by inflammation: Implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 3: 140-147
64. Pierangeli SS et al. (2005) Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 52: 2120-2124
65. Oku K et al. (2008) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis [doi:10.1136/ ard.2008.090670]
66. Straub A et al. (2005) The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 27: 617-621
67. Vega-Ostertag M et al. (2004) Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 50:2911-2919
68. Napoleone E et al. (2000) Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 86 139-143
69. Roubey RA (2003) New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations. Arthritis Rheum 48: 3004-3008
70. Kinev AV and Roubey-RA (2008) Tissue factor in antiphospholipid syndrome. Lupus 17:952-958
71. Burcoglu-O'Ral A et al. (2002) Treatment of catastrophic anti phospholioid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 29:2006-2011
72. Blank M et al. (2003) TNF alpha DNA vaccination prevents clinical manifastations of experimental antiphospholipid syndrome. Lupus 12:546-549
73. Berman J et al. (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174: 485-490
74. Jonsdottir T et al. (2004) Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63:1075-1078
75. Akkerman A et al. (2004) CTLA4lg prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 37:445-451
76. Biasucci LM et al. (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94:874-877.
77. Del Papa N et al. (1997) Endothelial cells as target for antiphospholipid antibodies. Human potyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum 40:551-561
78. Bernales I et al. (2008) Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 9: 38-46
79. Forastiero RR et al. (2005) Circulating levels of tissue factor and proinflammatory cytokines in patents with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 14:129-136
80. Salobir B and Sabovic M (2004) Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease. Obstet Gynecol 104: 564-570
81. Asherson RA et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-534